News | April 08, 2025
NATCO Pharma updates on legal proceedings on Risdiplam launch in India
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Awards highlight Avantor's commitment to the Biopharma industry
The portfolio includes branded injectable cephalosporines for infectious diseases
The company expects to launch this product through its marketing partner in the near future
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
AstraZeneca Pharma India discontinues manufacturing of Imdur
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subscribe To Our Newsletter & Stay Updated
